This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (193)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Nutritional and Metabolic Disorders  • Nutritional and Metabolic Disorders, Other  • Drug Therapy  • Schizophrenia  • Adverse Effects  • Alert me on articles by topic

John W. Newcomer, MD; Dan W. Haupt, MD; Robert Fucetola, PhD; Angela K. Melson, MA; Julie A. Schweiger; Benjamin P. Cooper, BA; Gregg Selke, BA

Arch Gen Psychiatry. 2002;59:337-345.

Background  Hyperglycemia and type 2 diabetes mellitus are more common in schizophrenia than in the general population. Glucoregulatory abnormalities have also been associated with the use of antipsychotic medications themselves. While antipsychotics may increase adiposity, which can decrease insulin sensitivity, disease- and medication-related differences in glucose regulation might also occur independent of differences in adiposity.

Methods  Modified oral glucose tolerance tests were performed in schizophrenic patients (n = 48) receiving clozapine, olanzapine, risperidone, or typical antipsychotics, and untreated healthy control subjects (n = 31), excluding subjects with diabetes and matching groups for adiposity and age. Plasma was sampled at 0 (fasting), 15, 45, and 75 minutes after glucose load.

Results  Significant time x treatment group interactions were detected for plasma glucose (F_12,222 = 4.89, P<.001) and insulin (F_12,171 = 2.10, P = .02) levels, with significant effects of treatment group on plasma glucose level at all time points. Olanzapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at all time points, in comparison with patients receiving typical antipsychotics as well as untreated healthy control subjects. Clozapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at fasting and 75 minutes after load, again in comparison with patients receiving typical antipsychotics and untreated control subjects. Risperidone-treated patients had elevations in fasting and postload glucose levels, but only in comparison with untreated healthy control subjects. No differences in mean plasma glucose level were detected when comparing risperidone-treated vs typical antipsychotic–treated patients and when comparing typical antipsychotic–treated patients vs untreated control subjects.

Conclusion  Antipsychotic treatment of nondiabetic patients with schizophrenia can be associated with adverse effects on glucose regulation, which can vary in severity independent of adiposity and potentially increase long-term cardiovascular risk.

From the Departments of Psychiatry (Drs Newcomer and Haupt, Mss Melson and Schweiger, and Messrs Cooper and Selke) and Neurology (Dr Fucetola), Washington University School of Medicine, St Louis, Mo.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Differential Effects of Various Typical and Atypical Antipsychotics on Plasma Glucose and Insulin Levels in the Mouse: Evidence for the Involvement of Sympathetic Regulation
Savoy et al.
Schizophr Bull 2008;0:sbn104v1-sbn104.
ABSTRACT | FULL TEXT  

Schizophrenia Host Vulnerability and Risk of Metabolic Disturbances During Treatment with Antipsychotics
Buckley et al.
Focus 2008;6:172-179.
ABSTRACT | FULL TEXT  

Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia
Fenton and Chavez
Focus 2008;6:246-253.
ABSTRACT | FULL TEXT  

Toward a Model of Memory Enhancement in Schizophrenia: Glucose Administration and Hippocampal Function
Stone and Seidman
Schizophr Bull 2008;34:93-108.
ABSTRACT | FULL TEXT  

Incidence of Schizophrenia in a Nationwide Cohort of Patients With Type 1 Diabetes Mellitus
Juvonen et al.
Arch Gen Psychiatry 2007;64:894-899.
ABSTRACT | FULL TEXT  

Schizophrenia, antipsychotics and metabolic disease
Reynolds
J Psychopharmacol 2007;21:355-356.
 

ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders
Noel
Am J Health Syst Pharm 2007;64:863-876.
FULL TEXT  

Life-Threatening Hyperglycemia and Acidosis Related to Olanzapine: A Case Report and Review of the Literature
Varma et al.
J Intensive Care Med 2007;22:52-55.
ABSTRACT  

Efficacy with High-Dose Aripiprazole After Olanzapine-Related Metabolic Disturbances
Chavez and Poveda
The Annals of Pharmacotherapy 2006;40:2265-2268.
ABSTRACT | FULL TEXT  

Aripiprazole in the Treatment of Delirium
Straker et al.
Psychosomatics 2006;47:385-391.
ABSTRACT | FULL TEXT  

Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia
Fenton and Chavez
Am. J. Psychiatry 2006;163:1697-1704.
FULL TEXT  

Blood glucose testing for adults prescribed atypical antipsychotics in primary and secondary care
Tarrant
Psychiatr. Bull. 2006;30:286-288.
ABSTRACT | FULL TEXT  

Hyperglycemia and Diabetes in Patients With Schizophrenia or Schizoaffective Disorders
Cohen et al.
Diabetes Care 2006;29:786-791.
ABSTRACT | FULL TEXT  

Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: Sensitivity to study design
Gianfrancesco et al.
Am J Health Syst Pharm 2006;63:431-441.
ABSTRACT | FULL TEXT  

Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia
Hosojima et al.
J Psychopharmacol 2006;20:75-79.
ABSTRACT  

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
Zipursky et al.
Br. J. Psychiatry 2005;187:537-543.
ABSTRACT | FULL TEXT  

Antagonism of the Serotonin (5-HT)-2 Receptor and Insulin Sensitivity: Implications for Atypical Antipsychotics
Gilles et al.
Psychosom. Med. 2005;67:748-751.
ABSTRACT | FULL TEXT  

Cost-Effective Screening for the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotic Medications
Straker et al.
Am. J. Psychiatry 2005;162:1217-1221.
ABSTRACT | FULL TEXT  

Inhibitory Effects of Antipsychotics on Carbachol-Enhanced Insulin Secretion From Perifused Rat Islets: Role of Muscarinic Antagonism in Antipsychotic-Induced Diabetes and Hyperglycemia
Johnson et al.
Diabetes 2005;54:1552-1558.
ABSTRACT | FULL TEXT  

Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs
Taylor et al.
J Psychopharmacol 2005;19:182-186.
ABSTRACT  

Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice
Tovey et al.
J Psychopharmacol 2005;19:207-210.
ABSTRACT  

Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis
Henderson et al.
Arch Gen Psychiatry 2005;62:19-28.
ABSTRACT | FULL TEXT  

Diabetic Keto-Acidotic (DKA) Coma following Olanzapine Initiation in a Previously Euglycaemic Woman and Successful Continued Therapy with Olanzapine
Howes and Rifkin
J Psychopharmacol 2004;18:435-437.
ABSTRACT  

A Comparison of Type 2 Diabetes Outcomes Among Persons With and Without Severe Mental Illnesses
Dixon et al.
Psychiatr. Serv. 2004;55:892-900.
ABSTRACT | FULL TEXT  

Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications
Cavazzoni et al.
Br. J. Psychiatry 2004;184:s94-s101.
ABSTRACT | FULL TEXT  

A Prospective Study of Impairment in Glucose Control Caused by Clozapine Without Changes in Insulin Resistance
Howes et al.
Am. J. Psychiatry 2004;161:361-363.
ABSTRACT | FULL TEXT  

Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Diabetes Care 2004;27:596-601.
FULL TEXT  

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: Magnetic resonance imaging study of previously untreated people with schizophrenia
ZHANG et al.
Br. J. Psychiatry 2004;184:58-62.
ABSTRACT | FULL TEXT  

Diet, smoking and cardiovascular risk in people with schizophrenia: Descriptive study
McCreadie
Br. J. Psychiatry 2003;183:534-539.
ABSTRACT | FULL TEXT  

Patients on Atypical Antipsychotic Drugs: Another High-Risk Group for Type 2 Diabetes: Response to Hardy and Breier
Lean and Pajonk
Diabetes Care 2003;26:3202-3203.
FULL TEXT  

Patients on Atypical Antipsychotic Drugs: Another High-Risk Group for Type 2 Diabetes: Response to Lean and Pajonk
Hardy and Breier
Diabetes Care 2003;26:3200-3201.
FULL TEXT  

Eruptive Xanthomas Associated With Olanzapine Use
Chang et al.
Arch Dermatol 2003;139:1045-1048.
ABSTRACT | FULL TEXT  

Low-Dose Clozapine and Diabetic Ketoacidosis
Lafayette et al.
Psychosomatics 2003;44:249-252.
FULL TEXT  

Effect of Acute Psychotic Stress in Nondiabetic Subjects on {beta}-Cell Function and Insulin Sensitivity
Shiloah et al.
Diabetes Care 2003;26:1462-1467.
ABSTRACT | FULL TEXT  

Patients on Atypical Antipsychotic Drugs: Another high-risk group for type 2 diabetes
Lean and Pajonk
Diabetes Care 2003;26:1597-1605.
ABSTRACT | FULL TEXT  

Pharmacological Agents That Directly Modulate Insulin Secretion
Doyle and Egan
Pharmacol. Rev. 2003;55:105-131.
ABSTRACT | FULL TEXT  

Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics
Lindenmayer et al.
Am. J. Psychiatry 2003;160:290-296.
ABSTRACT | FULL TEXT  

Dr. Sernyak and Colleagues Reply
SERNYAK et al.
Am. J. Psychiatry 2003;160:389-389.
FULL TEXT  

Adjunctive Olanzapine for SSRI-Resistant Combat-Related PTSD: A Double-Blind, Placebo-Controlled Study
Stein et al.
Am. J. Psychiatry 2002;159:1777-1779.
ABSTRACT | FULL TEXT  

Glucose Regulation Impaired by Atypical Antipsychotic Drugs
JWatch Psychiatry 2002;2002:1-1.
FULL TEXT